Curis (NASDAQ:CRIS) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Curis (NASDAQ:CRIS) in a research note published on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Curis in a research report on Tuesday, December 10th.

Curis Price Performance

Shares of CRIS stock opened at $2.10 on Friday. The firm has a market cap of $17.78 million, a P/E ratio of -0.27 and a beta of 3.49. The stock’s 50-day moving average is $3.01 and its two-hundred day moving average is $3.86. Curis has a fifty-two week low of $2.10 and a fifty-two week high of $17.49.

Institutional Trading of Curis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bleichroeder LP raised its holdings in Curis by 1,982.2% in the 4th quarter. Bleichroeder LP now owns 520,539 shares of the biotechnology company’s stock valued at $1,593,000 after acquiring an additional 495,540 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Curis during the fourth quarter valued at $607,000. Samsara BioCapital LLC bought a new position in Curis during the 4th quarter valued at about $607,000. CM Management LLC boosted its holdings in shares of Curis by 83.3% in the 4th quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after acquiring an additional 100,000 shares in the last quarter. Finally, M28 Capital Management LP raised its position in Curis by 23.5% in the 4th quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock valued at $1,594,000 after purchasing an additional 99,108 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.